Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok2. fázis

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

A legfontosabb adatok

Ki végzi
Derm Texas, PLLC
Hol
Dallas (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
20 fő, tervezett
Kezdés
2025. aug. 1.
Tervezett befejezés
2026. jún. 15.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Roflumilast topical 0.3% foam
A regiszteradat frissítve
2025. augusztus 8.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for children and teens with non-segmental vitiligo, including on the face. They will use Roflumilast foam 0.3% on the skin.

Életkor
2 years to less than 18 years
Nem
All sexes
A betegség stádiuma
Non-segmental vitiligo diagnosed for at least 3 months. Less than 10% of the body skin is affected, with at least 0.5% on the face. Some face patches still have coloured hair.
Korábbi kezelés
Cannot join after Roflumilast cream or foam for vitiligo in the past 3 months, or oral roflumilast within 4 weeks. Biologic or experimental therapy must stop 12 weeks (or 5 half-lives) before, light therapy and immune-changing treatments 4 weeks before, and skin treatments 1 week before.

A részvétel fő kizáró okai

  • Other types of vitiligo or other skin conditions that cause light patches
  • Severe kidney problems or moderate to severe liver problems (Child-Pugh B or C)
  • Allergy to an ingredient of Roflumilast foam
  • Cannot stop CYP3A4 inhibitor medicines taken by mouth or other routes
  • Pregnant, planning pregnancy or breastfeeding

A regiszter feltételei, szó szerint

Mind a 18 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female subjects aged 2 years but less than 18 years
  • Pediatric and adolescent subjects: Informed consent of parent(s) or legal guardian, and, if age appropriate, assent by the subjects, as required by local laws
  • Diagnosis of non-segmental vitiligo based on clinical history and dermatology examination for at least 3 months
  • Diagnosis of non-segmental vitiligo with the following:; BSA affected < 10% AND; At least 0.5% BSA affected on the face. AND; Pigmented hair within some of the areas of vitiligo on the face
  • In good health as judged by the Investigator, based on the medical history, and dermatology examination
  • Subjects and parent(s)/legal guardian (s) are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator

Ki nem vehet részt

  • Subjects with known or suspected:; Severe renal insufficiency; Moderate to severe hepatic disorders (Child-Pugh B or C); Subjects who cannot discontinue prohibited medications and treatments prior to the Baseline visit and during the study, including (any biologic or experimental therapy within 12 weeks (or 5 half-lives), phototherapy within 4 weeks, immunomodulating treatments within 4 weeks, or topical treatments within 1 week
  • Subjects who are unwilling to refrain from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline/Day 1 and during the study
  • Subjects who cannot discontinue systemic CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously (e.g. Erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine)
  • Subjects who have received oral roflumilast (Daxas®, Daliresp®) within 4 weeks prior to Baseline/Day 1
  • Previous treatment with Roflumilast cream or foam for vitiligo in the past 3 months
  • Subjects with any serious medical condition or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator
  • Subjects with diagnosis of other forms of vitiligo (e.g. Segmental), other differential diagnosis of vitiligo or other skin depigmentation disorders (e.g. Piedbaldism, pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma and tinea versicolor) that would interfere with the evaluations of the effect of the study medication, as determined by the Investigator
  • Subjects with known genetic dermatological conditions that overlap with non-segmental vitiligo
  • Known allergies to excipients in Roflumilast foam (petrolatum, isopopyl palmitate, methylparaben, propylparaben, diethylene glycol monomethyl ether, hexylene glycol, cetylseteary alcohol, dicetyl phosphase and ceteth-10 phosphate)
  • Parent (s)/legal guardians (s) who are unable to communicate, read, or understand the local language (s). Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation
  • Females who are pregnant, wishing to become pregnant during the study, or are breast feeding
  • Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects living in the same house

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 2 és 18 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Derm TexasDallas, Egyesült ÁllamokContact: Amanda Study CoordinatorRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)

A vizsgálat csoportja

  • Open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3%A vizsgált kezelés

    Kezelés: Roflumilast topical 0.3% foam

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT07105254: ki vehet részt
A regiszteradat frissítve
2025. augusztus 8.